Immuron | Evaluate

February 19, 2021

Immunome soars 76% on Covid-19 hopes – but that's nothing

Investors toast Galmed Nash results, but what will the FDA say?

February 13, 2017

Intercept strikes at the heart of the Nash problem

July 25, 2016

Despite a deck stacked in its favour, Tobira fails in NASH

May 03, 2016

Therapy focus – NASH projects set for data in dog days of summer

September 24, 2015

Conatus makes a splash in NASH

April 08, 2015

Astra first big pharma to dip toe in simmering NASH waters

March 10, 2015

NASH craze lives on, despite the unknowns

August 09, 2013

Sanofi brings prospect of C difficile vaccine closer